** Insmed's INSM.O shares down 1% after hours at $96.88 as biopharma co plans equity raise
** Bridgewater, New Jersey-based Insmed announces $650 mln stock offering
** Goldman Sachs and Leerink are jt bookrunners
** On Tues, INSM shares soared 29% after co said its inhaled drug, treprostinil palmitil, reduced blood pressure in the lungs and improved exercise capacity in patients in mid-stage study
** The shares added another 7.8% to close at $97.98 on Weds, a more than two-decade high
** Co plans to use net offering proceeds for continued R&D and development of its product candidates, per the SEC filing
** With ~182 mln shares outstanding, INSM has nearly $18 bln market cap
** Through Weds close, stock up 42% YTD
** All 19 analysts are bullish on INSM including 6 "strong buy" ratings; median PT of $110 up from $97 a month ago, latest LSEG data shows
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。